Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 25, 2003. The report details corporate actions regarding share re-purchases and updates on directors' interests in company shares held through employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific transactional data:
- Share Re-purchase: 850,000 ordinary shares purchased for cancellation on March 24, 2003, at 1169.99p per share.
- US Retirement Savings Plan: Holdings decreased from 18,698,323 to 18,619,074 Ordinary Share ADRs at an average price of $36.52.
- Employee Benefit Trust: Purchased 299,458 ordinary shares at £11.41 per share for the Annual Investment Plan.
Material Changes
The filing reports specific changes in share ownership structures rather than operational performance changes:
- Reduction in outstanding share count due to the cancellation of 850,000 shares.
- Decrease in the number of ADRs held by the US Retirement Savings Plan due to fund movements.
- Acquisition of new shares by the SmithKline Beecham Employee Benefit Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure of share transactions and director interest notifications.
Key Facts for Investor Verification
- Verify the total number of shares repurchased and cancelled against the authority granted at the May 20, 2002 Annual General Meeting.
- Confirm the impact of the share cancellation on the company's total share count and earnings per share.
- Review the specific holdings of directors Dr. J.P. Garnier and John Coombe within the discretionary employee funds to assess potential conflicts or exposure.
- Note that this filing does not contain quarterly or annual financial performance data.